ArticleEuropean journal of medical research2025
NDC80 promotes epithelial to mesenchymal transition of esophageal squamous cell carcinoma through macrophages polarization and PI3K/AKT pathway activation.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveEsophageal squamous cell carcinoma (ESCC) is a lethal malignancy with limited therapeutic options, primarily due to its aggressive metastatic behavior. This study aimed to elucidate the molecular drivers of ESCC metastasis by identifying a critical oncogene and investigate its functional mechanisms.
methodsUsing integrated bioinformatics screening, we identified NDC80 as a potential regulator of metastasis. The role and underlying mechanisms of NDC80 in ESCC progression have remained to be fully elucidated. We conducted in vitro functional assays-including real-time PCR, western blotting, and flow cytometry-to assess the effects of NDC80 on epithelial-mesenchymal transition (EMT) and malignant behavior. Mechanistic studies such as co-culture systems and ELISA, were used to evaluate tumor-associated macrophages (TAMs) polarization, with a specific focus on the PI3K/AKT pathway. In vivo, we established subcutaneous xenograft models in immunocompromised mice to validate the impact of NDC80 on ESCC progression. Clinical validation was performed using immunohistochemistry analysis of ESCC tissue samples.
resultsNDC80 was identified as a clinically significant oncogene, showing marked overexpression in ESCC tissues that was associated with advanced invasion depth, lymphatic metastasis, and vascular invasion. Functionally, NDC80 promoted tumor cell migration, invasion, and EMT progression. Mechanistically, NDC80 fostered a tumor-promoting microenvironment by inducing M2 macrophages polarization via secretion of M-CSF and CXCL-2, which in turn activated the PI3K/AKT pathway to further amplify EMT.
conclusionOur findings established NDC80 as a master regulator of ESCC metastasis by activating TAM-mediated PI3K/AKT and promoting EMT. These insights positioned NDC80 as a promising therapeutic target, offering a potential strategy to prevent ESCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.